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Abstract
Monosomy 7 [−7] and/or partial loss of chromosome 7 [del(7q)] are associated with poor and intermediate prognosis,
respectively, in myelodysplastic syndromes (MDS), but somatic mutations may also play a key complementary role. We
analyzed the impact on the outcomes of deep targeted mutational screening in 280 MDS patients with −7/del(7q) as isolated
cytogenetic abnormality (86 with del(7q) and 194 with −7). Patients with del(7q) or −7 had similar demographic and disease-
related characteristics. Somatic mutations were detected in 79% (93/117) of patients (82% in −7 and 73% in del(7q) group).
Median number of mutations per patient was 2 (range 0–8). There was no difference in mutation frequency between the two
groups. Patients harbouring ≥2 mutations had a worse outcome than patients with <2 or no mutations (leukaemic transformation
at 24 months, 38% and 20%, respectively, p= 0.044). Untreated patients with del(7q) had better overall survival (OS) compared
with −7 (median OS, 34 vs 17 months, p= 0.034). In multivariable analysis, blast count, TP53 mutations and number of
mutations were independent predictors of OS, whereas the cytogenetic subgroups did not retain prognostic relevance. This study
highlights the importance of mutational analysis in terms of prognosis in MDS patients with isolated −7 or del(7q).
Introduction
Recurrent chromosomal abnormalities occur in ~50% of
patients with myelodysplastic syndrome (MDS), and the
type and complexity of the aberrations correlate with
transformation into acute myeloid leukaemia (AML) and
overall survival (OS). Notably, isolated monosomy 7 (−7)
and/or partial loss of the long arm of chromosome 7 (del 7q)
and –7/del(7q) with additional cytogenetic aberration(s) are
the second most frequent chromosomal abnormalities in
MDS, and are associated with a poor OS and high trans-
formation rate to AML [1–5].
The most commonly used prognostic tools for evaluating
patients with MDS are the International Prognostic Scoring
System (IPSS) [6] and its revised version, the IPPS-R. In
the IPSS, chromosome 7 abnormalities were grouped into
the poor-risk chromosomal risk category. Given the
demonstration that isolated del(7q) and −7 have a different
impact on outcomes [7–10], these two different chromo-
some 7 abnormalities were segregated into different risk
categories in the IPSS-R [8, 11].
Median OS for patients with isolated del(7q) is between
20 and 40 months as compared with 9 and 20 months for
isolated −7 [7–10] (Supplementary data Table 1). However,
these studies included only untreated patients and were
limited by a small patient number; only 59 patients had
isolated abnormalities of chromosome 7 in the international
database on which IPSS-R was based [8].
There are three common deleted regions on 7q. These
include band 7q22 (the most frequent) and the more telo-
meric regions 7q31–32 and 7q36 [12–14], but they do not
seem to impact prognosis in a study by using SNP-A kar-
yotyping [10]. The role of chromosome 7 abnormalities in
the pathogenesis of MDS is not yet well characterised. It has
been proposed that either mutations (EZH2 [15–17]) or
specific gene haploinsufficiency [14, 18–22], or an
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epigenetic mechanism of silencing of genes located in the
7q-deleted region could play a role [10]. However,
unlike MDS with del(5q), a clear correlation between gen-
otype and phenotype has not been demonstrated for chro-
mosome 7 aberrations [23]. Moreover, if the partial and the
complete loss of chromosome 7 are sequential stepwise
events, the route to these abnormalities, and why these two
different defects of the same chromosome have a different
impact on prognosis, are still unclear.
The relationship between somatic gene mutations and
single chromosome 7 abnormalities, and the impact of the
former on the outcomes of this specific MDS patient
population, are unknown.
The purpose of this study was to describe the clinical
features, bone marrow (BM) characteristics and myeloid-
related somatic gene mutations in a large and well-
characterized cohort of MDS and MDS/myeloproliferative
neoplasm (MPN) patients with isolated abnormalities
involving chromosome 7. In particular, we aimed to assess
the independent prognostic relevance for the outcomes of




We evaluated 280 patients with MDS (N= 245) or MDS/
MPN (N= 35) who had either at diagnosis (N= 267) or
developed during follow-up (N= 13) a total or partial loss
of chromosome 7 as an isolated chromosomal abnormality.
The diagnosis was carried out on the basis of the World
Health Organization (WHO) classification 2008 [24]. We
excluded all patients with either complex or double
abnormalities that included −7 or del(7q).
Patients included in the study were referred by King’s
College Hospital NHS Trust, the Spanish MDS group
(GESMD), University Medical Center Göttingen, Uni-
versity Hospital Düsseldorf, the University of Turin and the
MDS Unit, AOUC, University of Florence. Informed con-
sent was obtained following the Declaration of Helsinki,
according to protocols approved by the review boards and
ethics committees of the participating institutions. Patients
and disease characteristics (age, sex, haemoglobin levels,
platelet counts, absolute granulocyte counts, percentage of
blasts in BM, BM cellularity and fibrosis (age-adjusted BM
cellularity and fibrosis were assessed on BM trephine,
according to European consensus [25, 26]), duration of
disease and de novo, secondary or therapy-related MDS),
transfusion dependency at diagnosis (defined according to
IWG 2006 criteria [27]), IPSS and IPSS-R prognostic
scores, administered therapies and previous diagnosis of
aplastic anaemia or other BM failure syndromes were col-
lected and included in the prognostic factor analyses.
Family history and clinical signs of familial disease were
checked and recorded in all the patients, particularly in the
younger ones. Patients in whom a disease with genetic
predisposition to MDS or inherited BM failure was diag-
nosed were excluded from this study.
The patients previously diagnosed with aplastic anaemia
were also screened to rule out Fanconi anaemia (by chro-
mosomal breakage analysis), Shwachman–Diamond syn-
drome and some common telomere biology diseases (by
mutational analysis of the genes TERC, TERT and TINF2).
Patients who acquired −7 or del(7q) over follow-up were
characterized from the time of the cytogenetic abnormality
detection.
Next-generation sequencing (NGS) analysis
BM samples at diagnosis or at the stage of first −7/del(7q)
detection were available for 117 of 280 patients; 84 of them
carried −7 and 33 del(7q). DNA extraction from BM total
nucleated cells was performed by using QIAamp DNA
extraction kit (Qiagen), according to the manufacturer’s
protocol. Gene mutation screening for commonly mutated
myeloid-related genes was performed by using King’s
College Hospital myeloid-gene panel. PCR amplification of
the coding regions or known hotspots of genes including
ASXL1, BCOR, CBL, CEBPA, DNMT3A, ETV6, EZH2,
FLT3, GATA2, IDH1, IDH2, JAK2, KDM6A, KIT, KRAS,
NPM1, NRAS, RUNX1, SF3B1, SRSF2, STAG2, TET2,
TP53, U2AF1 and ZRSR2 was performed as described
previously [28] (Supplementary Table 2). This method was
designed to detect somatic nucleotide variants and small
insertions/deletions (<50 bp) within the coding regions of
the targeted genes. Sequencing was performed using the
MiSeq Instrument with version −2 or −3 sequencing
chemistry (Illumina, San Diego, CA, USA), as per the
manufacturer’s instructions. Sequencing data were pro-
cessed using the GATK pipeline package (Broad Institute,
Boston, MA, USA). Processed VCF and BAM files were
visualised using variant studio (Illumina) and integrated
genome viewer, respectively. Variants were excluded if the
Q score was less than 30, total read depth <200, variant
allele frequency (VAF) <5% and presence of strand bias,
present in 5′UTR, 3′UTR, noncoding RNA, intronic region
were synonymous. Deletions and duplications were inclu-
ded. Unreported variants were excluded if outside the hot-
spot in ‘hotspot genes’. All variants with a population allele
frequency of >1% described in dbSNP132, ESP5400 and
1000 genomes project were considered as common SNPs
and were also excluded. The variants were assessed in
context with their somatic status and frequency in published
cancer databases—COSMIC (Catalogue of Somatic
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Mutations in Cancer), ClinVar, The Cancer Genome Atlas
database and large published studies on the genomic land-
scape of AML and MDS. VAF for EZH2 was analyzed
without correction for loss of heterozygosity.
Statistical methods
Demographic and clinical covariates were compared using
the Kruskal–Wallis test for continuous variables and Pear-
son’s chi-square test for categorical variables. OS was
estimated by using the Kaplan–Meier method, and any
statistical difference between curves was assessed by using
log-rank tests. OS was defined as the time elapsed between
diagnosis and death or the last follow-up. To analyze the
impact of therapeutic choice and mutations on survival,
patients who underwent allogeneic haematopoietic cell
transplantation (allo-HCT) were censored at the time of
transplantation. In survival analysis that included allo-HCT
as a variable, we censored patients at death or the last
follow-up. AML-free survival was defined as the time
elapsed from diagnosis to AML diagnosis. AML cumulative
incidence risk was calculated by the cumulative function
with death without AML progression considered as a
competing event.
Cox proportional hazards models were used to compare
the different risk factors by the Wald test: gender, age at
diagnosis (>65 vs ≤65 years), isolated −7 vs del(7q),
diagnosis (according to WHO), primary vs therapy-related
disease, BM blasts (categorised as <5%, 5–10% and
11–19%), BM cellularity (hypocellular, normocellular and
hypercellular), first-line therapy, allo-HCT and gene
somatic mutations.
Multivariate analysis using the Cox proportional hazards
regression method for temporal events was used to identify
the most significant independent prognostic variables for
OS and AML transformation. The characteristics selected
for possible inclusion in the multivariate model were those
for which there was some indication of a significant asso-
ciation with OS or AML transformation in the univariate
analysis. Only cases with complete data for all variables
were included in the regression procedure.
All reported P values were two sided, and the conven-
tional 5% significance level was used for defining statisti-
cally significant differences. Data were analyzed as of
February 2019 by SPSS 20.0.0 and R package.
Results
Patients’ characteristics
We included 280 patients, 194 with −7 and 86 with del(7q).
Median follow-up was 26 months (range 1–182 months).
Median age at diagnosis was 65 years (range 16–88 years).
Patients with −7 had a lower platelet count at presentation,
and were at higher IPSS-R risk than patients with del(7q),
p < 0.001 and p < 0.001, respectively. No other statistically
significant difference in demographic, patient and disease
characteristics was observed between the two groups
(Table 1). Of note, the percentage of patients with hypo-
cellular marrow (26%) was slightly higher than expected in
an MDS population (10–20%) [29, 30].
Moreover, patients with hypocellular marrow were
slightly younger than the others, as median age was 61
years in the hypocellular group, 64 in the normocellular
group and 66 in the hypercellular group. However, the age
distribution was not statistically different in the three groups
(p= 0.671).
Interestingly, 12 patients were previously diagnosed with
aplastic anaemia, and 11 out of 12 had −7 at transformation
to MDS, whereas only one presented with del(7q).
In all those 12 patients, other congenital BM failure
diseases were excluded, as previously described in this
section ‘Methods’.
There was no significant correlation between cellularity
and previous aplastic anaemia (at the MDS stage, three
patients with aplastic anaemia had a normocellular marrow,
three hypercellular marrow and six hypocellular marrow,
p= 0.170).
Treatment
Data on treatment were available for 266 patients, and no
significant differences were noted in the treatments received
between the cytogenetic subgroups.
Overall, 139 of 266 (52%) patients were treated. Out of
139 (21%) patients, 29 received intensive chemotherapy
(IC) as first-line treatment (an induction course followed by
one to two consolidation courses with either fludarabine+
cytarabine+ idarubicin, or cytarabine+ idarubicin+ eto-
poside, or standard ‘3+ 7’ with daunorubicin or idar-
ubicin), 80 (58%) azacitidine (AZA) for a median of six
courses (range 1–19), 12 (9%) immunosuppressive drugs
(including cyclosporine and steroids), 10 (7%) allo-HCT
and 8 (6%) other therapies (including hydroxycarbamide,
thalidomide, lenalidomide and low-dose cytarabine). Fifty-
five patients (21%) underwent allo-HCT: 22 after receiving
IC, 13 after AZA, 8 after AZA and IC, 2 after immuno-
suppressive treatment and 10 upfront.
Patients receiving IC were younger than patients treated
with AZA, median age 49 vs 71, respectively, p < 0.001.
Mutational data
Somatic mutations were found in 79.5% (93/117) of
patients; 82% (69/89) in −7 and 73% (24/33) in del(7q)
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group (p= 0.256). Median number of mutations per patient
was 2 (range 0–8) with 54 and 49% of −7 and del(7q)
patients harbouring ≥2 mutations, respectively (P= 0.521).
VAF of all genes according to −7 or del(7q) is shown in
Fig. 1. There was no difference in mutation distribution or
VAF between the two groups (Figs. 1 and 2).
Overall, 54% of patients had mutations in genes involved
in epigenetic and chromatin modifications, 30% in splicing
factors, 20% in cell signalling and 33% in transcription
factors (Fig. 3). U2AF1 mutations were associated with
lower haemoglobin level (8 g/dL vs 10,2 g/dL, P < 0.001
and platelets 84 × 109/L vs 123 × 109/L, P 0.046), whereas
patients with TET2 mutation had higher WBC count
(10.6 × 109/L vs 3.2 × 109/L, P= 0.018). Patients who har-
boured ≥1 mutation were older (median age, 54, 65 and 67
years in patients with 0, 1 and 2 or more mutations,
respectively; P= 0.046). In particular, TET2 and TP53
mutations were associated with older age compared with
patients without mutations (P= 0.010 and 0.008,
respectively).
In this cohort of patients, the percentage of mutations in
genes involved in methylation and chromatin modification
(in particular ASXL1, DNMT3A and EZH2), and in other
genes known to have an adverse prognostic impact [31, 32]
(i.e. RUNX1, U2AF1, NRAS and ETV6), was higher than
previously described [31, 33, 34] in MDS patients. On the
contrary, we observed fewer patients with TET2, SF3B1,
SRSF2 and STAG2 mutations (Fig. 2).
Of the eight patients with a previous history of aplastic
anaemia, in whom samples were available, mutations were
detected in 62% of them, and only three patients had ≥2
mutation (range 1–5). The most frequently mutated gene
was ASXL1 (mutated in four patients), followed by EZH2
and RUNX1 (two patients, respectively) and U2AF1, SF3B1
and CBL in one patient each. No mutations in BCOR were
found in this cohort.
Overall survival and response to treatment
In this large series, OS for del(7q) patients was longer
compared with −7 patients, but this difference was not
statistically significant (median OS 34 months vs
27 months, respectively; P= 0.268) (Fig. 4b). However, as
expected, there was a statistically significant difference in
OS between the two cytogenetic groups in untreated
patients (n= 127) and favouring del(7q) cases (median OS
34 vs 17 months, P= 0.034 (Fig. 4a)).
Of note, there was no difference in response rates to
AZA or IC or immunosuppressive drugs in patients with del
(7q) or −7 (data available for 92 patients only) (Supple-
mentary data Table 3).
There was no difference in OS between patients treated
with IC or AZA front line (median OS 35 vs 28 months,
p= 0.297). However, patients who underwent allo-HCT
had a longer OS (median 35 vs 26 months, P= 0.003),
regardless of the allo-HCT pre-treatment. Of note, median
age of transplanted patients was 50 years, and 62% were
<60 years old.
The 12 patients previously diagnosed with aplastic
anaemia had a similar outcome as compared with de novo
MDS (median OS censored at allo-HCT, 32 vs 28 months,
P= 0.678), even if the long-term outcome was better as 9
out of 12 underwent allo-HCT. In particular, in this small
subset of patients, there was no difference in OS and AML
cumulative incidence risk according to the presence of
mutations.
We also performed all the survival analysis without the
12 patients who developed MDS after a diagnosis of
aplastic anaemia and there was no change in patients’ out-
come (detailed analysis in Supplementary data, including
multivariable analysis in Table 4).
Table 1 Patient characteristics at diagnosis.
All patients −7 del(7q)
No (%) No (%) No (%) P value
Gender 0.482
Male 181 (65) 128 (66) 53 (62)
Female 99 (35) 66 (34) 34 (38)
Median age at diagnosis
(range)
65 (16–88) 64 (16–88) 65 (16–88) 0.554
<30 years 18 (6) 14 (7) 4 (5)
30–49 years 37 (13) 27 (14) 10 (12)
50–64 years 84 (31) 56 (29) 28 (32)
65–79 years 110 (39) 79 (41) 31 (36)
>80 years 31 (11) 18 (9) 13 (15)
WHO subtype 0.811
RA 20 (7) 11 (6) 9 (11)
RARS 10 (4) 7 (4) 3 (3)
RCMD 90 (32) 61 (31) 29 (34)
RAEB1 51 (18) 37 (19) 14 (16)
RAEB2 63 (21) 44 (23) 20 (23)
MDS-U 10 (4) 7 (4) 3 (3)
CMML 29 (10) 22 (10) 7 (8)
MDS/MPN 6 (2) 5 (3) 1 (1)
Therapy-related disease 32 (12) 23 (12) 9 (10) 0.640
Cellularity 0.738
Normocellular 56 (32) 39 (31) 17 (35)
Hypocellular 46 (26) 32 (26) 14 (29)
Hypercellular 72 (41) 54 (43) 18 (37)
Transfusion dependency 0.498
Yes 87 (40) 58 (38) 29(43)
No 131 (60) 93 (62) 38 (57)
IPSS 0.396
Intermediate1 42 (18) 25 (15) 17 (23)
Intermediate2 130 (55) 91 (56) 39 (52)
High 65 (27) 46 (28) 19 (25)
IPSS-R <0.001
Low 27 (13) 11 (8) 16 (27)
Intermediate 52 (26) 34 (24) 18 (30)
High 61 (30) 43 (30) 18 (30)
Very high 61 (30) 53 (38) 8 (13)
ANC (x109 /L) 1.36 (0.0–48.4) 1.33 (0.0–48.4) 1.30 (0.1–12.4) 0.753
HB (g/dL) 10 (3.0–16.0) 10 (3.0–15.0) 10 (5–16.0) 0.161
PLTS (x109 /L) 88 (3–794) 83 (3–597) 122 (8–794) <0.001
2444 E. Crisà et al.
Impact of somatic mutations on survival and
response to therapy
In univariable analysis, patients who harboured ≥2
mutations of any of the genes in the panel had a worse
outcome than patients without any mutation (P= 0.035)
or with only one mutation (P= 0.016) (Fig. 5), regardless
of the cytogenetic group. TP53 mutations were confirmed
as a strong predictor of poor outcome, regardless of the
small number of patients with mutations (P < 0.001),
together with mutations in splicing factors (P= 0.014)
and in NRAS (P= 0.017). By contrast, patients with
BCOR mutations had a longer survival than wild-type
patients (P= 0.050).
Mutations in splicing factors were associated with a
worse outcome when considered altogether, including
SF3B1. However, by taking the splicing factor genes
individually, none of them impacted significantly on OS,
even if U2AF1 and SRSF2 had a trend towards shorter
survival, and SF3B1 towards longer survival (of note,
only seven patients carried a mutation in SF3B1, of whom
only three as isolated mutation). We also performed the
survival analysis without SF3B1 in the splicing factor











































































































































































































Fig. 1 Variant allele frequency (VAF) of all genes according to −7 or del(7q).
Fig. 2 Mutation distribution
across del(7q) and −7 patients.
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mutations and worse outcome was confirmed (p = 0.017).
The lack of statistical significance of the impact of single-
gene mutations was probably due to low patient number in
each subcategory.
On multivariable analysis, the number of mutations of
any of the genes in the panel was confirmed as an inde-
pendent prognostic factor for OS together with percentage
of BM blasts and presence of TP53 mutations, whereas del
(7q)/−7 were not (Table 2).
We also analyzed separately the impact of single-gene
mutation in del(7q) patients and −7 patients, but due to a
small number of mutations in each cytogenetic subgroup
and coexistence of multiple mutations, the results were
not conclusive and additionally did not allow multi-
variable analysis (see Supplementary results for more
information).
We were able to correlate the response rate to therapy
and the presence of mutations in only 62 patients. However,
in patients treated first-line either with IC (n= 14) or AZA
(n= 39), there was a superior response rate (complete
response, partial response and haematological improve-
ment) in those without mutations than in patients with
mutations, 100% vs 29 and 100% vs 43%, respectively. By
contrast, no difference in response to immunosuppressive
treatment (n= 9) was observed according to mutations
(Supplementary data Table 3).
Fig. 3 Mutation frequency in the whole population and within −7 and del(7q) patients.
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Fig. 4 Overall survival according to chromosome 7 abnormality. a Untreated patients: isolated −7 (median 17 months) vs del(7q) (median
34 months). b All patients −7 (median 27 months) vs del(7q) (median 34 months).
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Finally, there was no difference in OS according to the
presence of somatic mutations at diagnosis in patients who
underwent allo-HSCT (P= 0.470).
AML transformation
There was no difference in cumulative incidence of AML
transformation between −7 and del(7q) patients. Cumula-
tive incidence of AML at 24 and 60 months was 28 and
35% in the −7 group and 22 and 38% in the del(7q) group,
respectively (P= 0.866). However, AML cumulative inci-
dence rates at 2 and 5 years were significantly higher in
patients with ≥2 mutations than in patients with 1 or no
mutation (38% vs 20% at 2 years and 49% vs 25% at 5
years, respectively, P= 0.044, Fig. 6).
At AML progression, 6 of 39 patients in whom kar-
yotype was available displayed a complex karyotype; the
other 33 maintained an isolated −7/del (7q).
Discussion
In the largest series to date of patients with MDS or related
myeloid neoplasms carrying isolated chromosome 7
abnormalities, we were able to show the relevant and
independent role of the number of somatic mutations and of
specific gene mutations in response to therapy and long-
term outcomes.
Of note, our cohort of patients showed a younger age
(median 65 years, confirmed also excluding MDS/MPN
patients) than expected in MDS and largely comprised
treated patients (52%). Interestingly, in contrast to the
results by Cordoba et al. [7] that showed a higher percen-
tage of patients with high-risk disease in the −7 cohort,
48% of the patients in the −7 group had a lower-risk disease
with less than 5% of blasts in BM, similar to the del(7q)
group. Moreover, apart from platelet count, we could not
find any other difference in disease characteristics across the
two groups, including frequency and distribution of somatic
mutations.
In line with the findings reported in other studies [7–
9, 35], untreated patients with isolated del(7q) had a better
outcome than patients with −7. However, this difference
was strongly attenuated in treated patients. This may
suggest that the two different chromosomal abnormalities
do not confer a different sensitivity to treatment or ther-
apy, possibly improving outcomes in −7 compared with
del(7q).
Patients who harboured one or more mutation were older
than wild-type patients. It is universally accepted that aging
favours mutation development [36] and accumulation of
mutations may occur stepwise, possibly over quite a long
time. However, in multivariable analysis the number of
mutations was a predictor of OS independently of
patients’ age.
In this study, we also observed a higher percentage of
somatic mutations in genes involved in methylation and
chromatin modifications than expected in MDS patients
[33, 34]. These data might explain the previously described
greater sensitivity of −7 patients to AZA treatment [37]. By
contrast, there were fewer TET2-mutated patients, probably
due to younger age, and also a lower number of SF3B1-
mutated patients, as only few patients had MDS with ring
sideroblasts.
Furthermore, there was also a high frequency of muta-
tions in genes associated with adverse prognosis in previous
studies, in particular ASXL1, DNMT3A, RUNX1, U2AF,
NRAS and ETV6 [31, 32], whereas the incidence of muta-
tions in TP53 was low. Indeed, harbouring a mutation of
either one of the splicing factors or TP53 or NRAS had an
adverse and independent effect on OS, and this poor out-
come was also seen in patients with ≥2 mutations in any of
the examined genes, as previously shown in other studies
[33, 38].
It has been shown that somatic mutations that detected
pre-allo-HCT may affect OS after transplant [39, 40]. In our
study, no difference in OS according to mutation at diag-
nosis in the subset of transplanted patients was observed.
However, mutational status immediately prior to transplant
was not available, and the effect of mutations may have
been confounded by other variables, especially treatment
pre-allo-HCT.
This series also confirmed that the partial loss of chro-
mosome 7 has a more favourable effect on outcomes than
the total loss, especially in untreated patients. However, the
somatic gene mutational pattern blurred the impact on OS
by the two chromosome 7 cytogenetic subgroups. Impor-
tantly, in patients treated both with AZA and IC, the
months
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Fig. 5 Overall survival by mutation number: no mutation (median
38 months), one mutation (median 65 months) and two or more
mutations (median 27 months).
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presence of somatic mutations impacted OS whereas the
cytogenetic subgroup did not. This may suggest that
the chemosensitivity of the MDS clone correlates more with
the mutational pattern than with the type of chromosome 7
abnormalities.
In summary, the data suggest that indeed there is a dif-
ference in OS between −7 and del(7q), but more impor-
tantly blast cell percentage and the number and type of
mutations are more relevant in terms of prognosis, and
possibly, response to therapy.
This study adds further evidence to the emerging data
demonstrating the added value of somatic mutations on risk
stratification and therapeutic decisions in MDS and AML
[31, 33, 41], possibly improving the one achieved by
cytogenetic abnormalities alone. Whether NGS results
should be currently included in clinical routine practice is
still debatable [42]. Undoubtedly, as they add relevant
prognostic information, the standardisation of performing
and reporting NGS techniques before their universal use
must be considered as a high priority.
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